- Salivary levels of HPV DNA are associated with locoregional disease in patients with HPV-associated oropharyngeal cancer (OPC).
Why this matters
- HPV DNA measurement might represent a noninvasive tool for predicting treatment response.
- Recurrent, persistent locoregional disease was associated with higher median baseline normalized salivary HPV DNA compared with distant disease only (10.9 vs 0.6 copies/ng; P=.01).
- Total tumor burden in patients with locoregional disease was associated with HPV DNA levels (P=.02).
- HPV DNA >5 copies/ng had 87% sensitivity and 67% specificity for prediction of locoregional disease.
- Salivary HPV DNA declined in all patients with locoregional disease response while receiving treatment.
- Subjects who responded to locoregional cytotoxic therapy with or without radiation had a median decline in salivary HPV DNA by 3.8% per day.
- Greater Royal Marsden Hospital prognostic score correlated with higher median plasma HPV cell-free DNA levels (P<.01 but this was not significant for normalized salivary hpv dna level>
- 21 patients with incurable or metastatic HPV-associated OPC were included.
- Funding: Expect Miracles Foundation; American Cancer Society; Robert A. and Renee E. Belfer Foundation.
- Small patient sample size.
- Observational study.